Bioavailability of intranasal scopolamine in normal subjects

Lakshmi Putcha, Karen J. Tietze, David W A Bourne, Cecelia M. Parise, Robert P. Hunter, Nitza Cintron

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The bioavailabilily of scopolamine in three dosage forms was compared in 12 healthy nonsmoking male volunteers. Subjects received 0.4-mg doses of scopolamine bromide in intravenous (IV), intranasal (IN), or oral (PO) dosage forms on three occasions, with at least 2 weeks separating the doses. Scopelamine concentrations in plasma were determined with a combined reverse- phase liquid chromatographic-radioreceptor binding assay. Saliva volume and flow rate and percent suppression of control flow rate were determined from each sample. Absorption after IN and PO scopolamine administration was rapid; plasma concentrations [1680 (IN) and 164 pg/mL (PO)] peaked within 1 h of dosing [0.37 (IN) and 0.78 h (PO)], respectively. IN and IV scopolamine suppressed salivary flow rate to similar extents (95% and 99.7%), respectively. Times to reach maximum effect were 1.05 and 0.27 h after IN and IV dosage, respectively. Absolute intranasal bioavailability, calculated from the area under the drug concentration vs time curve, was found to be significantly greater than that of PO scopolamine (83% vs 3.7%, p < 0.05). The IN route may provide a noninvasive, reliable, fast, and effective route for administering scopolamine.

Original languageEnglish (US)
Pages (from-to)899-902
Number of pages4
JournalJournal of Pharmaceutical Sciences
Volume85
Issue number8
DOIs
StatePublished - Aug 1996
Externally publishedYes

Fingerprint

Scopolamine Hydrobromide
Biological Availability
Flow rate
Dosage Forms
Plasmas
Radioligand Assay
Bromides
Saliva
Volunteers
Assays
Liquids
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Putcha, L., Tietze, K. J., Bourne, D. W. A., Parise, C. M., Hunter, R. P., & Cintron, N. (1996). Bioavailability of intranasal scopolamine in normal subjects. Journal of Pharmaceutical Sciences, 85(8), 899-902. https://doi.org/10.1021/js950327b

Bioavailability of intranasal scopolamine in normal subjects. / Putcha, Lakshmi; Tietze, Karen J.; Bourne, David W A; Parise, Cecelia M.; Hunter, Robert P.; Cintron, Nitza.

In: Journal of Pharmaceutical Sciences, Vol. 85, No. 8, 08.1996, p. 899-902.

Research output: Contribution to journalArticle

Putcha, L, Tietze, KJ, Bourne, DWA, Parise, CM, Hunter, RP & Cintron, N 1996, 'Bioavailability of intranasal scopolamine in normal subjects', Journal of Pharmaceutical Sciences, vol. 85, no. 8, pp. 899-902. https://doi.org/10.1021/js950327b
Putcha, Lakshmi ; Tietze, Karen J. ; Bourne, David W A ; Parise, Cecelia M. ; Hunter, Robert P. ; Cintron, Nitza. / Bioavailability of intranasal scopolamine in normal subjects. In: Journal of Pharmaceutical Sciences. 1996 ; Vol. 85, No. 8. pp. 899-902.
@article{b8107171206a4ae49657b815f440ecce,
title = "Bioavailability of intranasal scopolamine in normal subjects",
abstract = "The bioavailabilily of scopolamine in three dosage forms was compared in 12 healthy nonsmoking male volunteers. Subjects received 0.4-mg doses of scopolamine bromide in intravenous (IV), intranasal (IN), or oral (PO) dosage forms on three occasions, with at least 2 weeks separating the doses. Scopelamine concentrations in plasma were determined with a combined reverse- phase liquid chromatographic-radioreceptor binding assay. Saliva volume and flow rate and percent suppression of control flow rate were determined from each sample. Absorption after IN and PO scopolamine administration was rapid; plasma concentrations [1680 (IN) and 164 pg/mL (PO)] peaked within 1 h of dosing [0.37 (IN) and 0.78 h (PO)], respectively. IN and IV scopolamine suppressed salivary flow rate to similar extents (95{\%} and 99.7{\%}), respectively. Times to reach maximum effect were 1.05 and 0.27 h after IN and IV dosage, respectively. Absolute intranasal bioavailability, calculated from the area under the drug concentration vs time curve, was found to be significantly greater than that of PO scopolamine (83{\%} vs 3.7{\%}, p < 0.05). The IN route may provide a noninvasive, reliable, fast, and effective route for administering scopolamine.",
author = "Lakshmi Putcha and Tietze, {Karen J.} and Bourne, {David W A} and Parise, {Cecelia M.} and Hunter, {Robert P.} and Nitza Cintron",
year = "1996",
month = "8",
doi = "10.1021/js950327b",
language = "English (US)",
volume = "85",
pages = "899--902",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Bioavailability of intranasal scopolamine in normal subjects

AU - Putcha, Lakshmi

AU - Tietze, Karen J.

AU - Bourne, David W A

AU - Parise, Cecelia M.

AU - Hunter, Robert P.

AU - Cintron, Nitza

PY - 1996/8

Y1 - 1996/8

N2 - The bioavailabilily of scopolamine in three dosage forms was compared in 12 healthy nonsmoking male volunteers. Subjects received 0.4-mg doses of scopolamine bromide in intravenous (IV), intranasal (IN), or oral (PO) dosage forms on three occasions, with at least 2 weeks separating the doses. Scopelamine concentrations in plasma were determined with a combined reverse- phase liquid chromatographic-radioreceptor binding assay. Saliva volume and flow rate and percent suppression of control flow rate were determined from each sample. Absorption after IN and PO scopolamine administration was rapid; plasma concentrations [1680 (IN) and 164 pg/mL (PO)] peaked within 1 h of dosing [0.37 (IN) and 0.78 h (PO)], respectively. IN and IV scopolamine suppressed salivary flow rate to similar extents (95% and 99.7%), respectively. Times to reach maximum effect were 1.05 and 0.27 h after IN and IV dosage, respectively. Absolute intranasal bioavailability, calculated from the area under the drug concentration vs time curve, was found to be significantly greater than that of PO scopolamine (83% vs 3.7%, p < 0.05). The IN route may provide a noninvasive, reliable, fast, and effective route for administering scopolamine.

AB - The bioavailabilily of scopolamine in three dosage forms was compared in 12 healthy nonsmoking male volunteers. Subjects received 0.4-mg doses of scopolamine bromide in intravenous (IV), intranasal (IN), or oral (PO) dosage forms on three occasions, with at least 2 weeks separating the doses. Scopelamine concentrations in plasma were determined with a combined reverse- phase liquid chromatographic-radioreceptor binding assay. Saliva volume and flow rate and percent suppression of control flow rate were determined from each sample. Absorption after IN and PO scopolamine administration was rapid; plasma concentrations [1680 (IN) and 164 pg/mL (PO)] peaked within 1 h of dosing [0.37 (IN) and 0.78 h (PO)], respectively. IN and IV scopolamine suppressed salivary flow rate to similar extents (95% and 99.7%), respectively. Times to reach maximum effect were 1.05 and 0.27 h after IN and IV dosage, respectively. Absolute intranasal bioavailability, calculated from the area under the drug concentration vs time curve, was found to be significantly greater than that of PO scopolamine (83% vs 3.7%, p < 0.05). The IN route may provide a noninvasive, reliable, fast, and effective route for administering scopolamine.

UR - http://www.scopus.com/inward/record.url?scp=0029761048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029761048&partnerID=8YFLogxK

U2 - 10.1021/js950327b

DO - 10.1021/js950327b

M3 - Article

VL - 85

SP - 899

EP - 902

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 8

ER -